These studies raise the exciting possibility that G4-stabilizing molecules may prove to be an effective cancer therapy in patients with defects in HR proteins such as BRCA1 and BRCA2, providing a “synthetic lethal” approach to cancer therapy for these patients. This evidence concerns the gene BRCA2 and cancer.